Replies to post #268040 on Avid Bioservices Inc (CDMO)

[exwannabe]

I did not bring up this dataset for the exact reason that you stated.

It was BioBS who brought it up in response to Entdoc's request for numbers. He explicitly called out table 3, and I commented on this. Kind of funny that BioBS has a "great find" but if somebody actually looks at it and comments they are bring up FUD.

Anyway, if you just want to cherry pick some phrases out of the results [we both are looking at the same link], then how about:

Treatment-related AEs were reported in 34 patients (43%) in the placebo/bavituximab 1 mg/kg group and in 25 patients (63%) in the bavituximab 3 mg/kg group.

[That is almost stat sig]

Grade 3 treatment-related AEs occurred in 22 patients (55.0%) in the bavituximab 3 mg/kg group and in 35 patients (44.3%) in the combined control group. In the bavituximab 3 mg/kg arm